Correction to “Masking the transmembrane region of the amyloid β precursor protein as a safe means to lower amyloid β production”

IF 4.9 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2024-04-09 DOI:10.1002/trc2.12468

引用次数: 0

Abstract

Khan, A, Killick, R, Wirth, D, et al. Masking the transmembrane region of the amyloid β precursor protein as a safe means to lower amyloid β production. Alzheimer's Dement. 2023; 9:e12428. https://doi.org/10.1002/trc2.12428

The figure images are placed in the wrong order in the paper: The image for Figure 1 should be for Figure 2, the image for Figure 2 should be for Figure 3, and the image for Figure 3 should be for Figure 1. The correct order of the figures with matching legends are below:

We apologize for this error.

Abstract Image

查看原文本刊更多论文

对 "屏蔽淀粉样β前体蛋白跨膜区作为降低淀粉样β生成的安全手段 "的更正

Khan, A, Killick, R, Wirth, D, et al. 屏蔽淀粉样β前体蛋白的跨膜区作为降低淀粉样β生成的安全手段Alzheimer's Dement.2023; 9:e12428。https://doi.org/10.1002/trc2.12428The 图表图像在论文中的放置顺序有误：图1的图像应为图2的图像，图2的图像应为图3的图像，图3的图像应为图1的图像。正确的图序和图例如下：我们对这一错误表示歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.